TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03498235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: In Team Sevoflurane,patients undergo sevoflurane.
Study: NCT03308643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
Study: NCT02288871

Intervention type: RADIATION
Group type: OTHER
Intervention: Cardiac CT-scan
Description: ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves.
Study: NCT03498235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In Team Propofol ,anesthesia is maintained with propofol
Study: NCT02916446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 mcg
Study: NCT00472212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Hyperopic spectacle lenses
Study: NCT01946802

Intervention type: DEVICE
Intervention: Frontal 4 channel EEG
Description: Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
Study: NCT00452257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
Study: NCT01332201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study: NCT00472212

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Plano (no power, control) spectacle lenses
Study: NCT01282320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention program
Description: Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
Study: NCT02916446

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02472483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Behavior Therapy (CBT)
Description: 20-weeks CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Behavior Therapy (CBT)
Description: 20-weeks CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Behavior Therapy (CBT)
Description: 20-weeks CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: 8-weeks MBCT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: 8-weeks MBCT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: 8-weeks MBCT
Study: NCT00118144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT00863668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz + Tenofovir DF/Emtricitabine
Description: 600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
Study: NCT00604786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Dosing is based on IgE level and weight given every 2 or 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosing is based on IgE level and weight given every 2 or 4 weeks
Study: NCT01518114

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
Study: NCT03993405

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic evaluation
Description: Ultrasonographic measurement is assessment method to diagnosis of sarcopenia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic evaluation
Description: Ultrasonographic measurement is assessment method to diagnosis of sarcopenia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation
Description: Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
Study: NCT01398501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral, 200 to 400 mg QD or BID
Study: NCT00863668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir + Tenofovir DF/Emtricitabine
Description: 400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with biopsies
Description: Day 0, Day 2, Day 7, Day 14, Week 52
Study: NCT01438671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit
Description: The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional balance training
Description: This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
Study: NCT00863668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with biopsies
Description: Day 0, Day 2, Day 7, Day 14, Week 52

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Lymph Node Excision
Description: Day 0, Day 2, Day 7, Day 14, Week 52

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal Lymph Node Excision
Description: Day 0, Day 2, Day 7, Day 14, Week 52
Study: NCT01480180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Administered i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Administered i.v.
Study: NCT01039168

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workplace dialogue

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care as usual
Study: NCT00936949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical approach
Description: Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified lateral approach
Description: The operative technique described modified lateral approach as described by Mulliken et al.
Study: NCT02585791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene Glycol
Description: inhaled Propylene Glycol (PG) by vaporing
Study: NCT01631552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy (SG)
Description: Administered via intravenous (IV) infusion
Study: NCT03480763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study: NCT00725322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Saline
Description: Subcutaneous Saline injection given at site of scar neuroma
Study: NCT00990535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Description: Octreotide-LAR 30 mg administered every 21 days until progression
Study: NCT03072030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEvac-Combi (vaccine)
Description: vaccination

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vaccination
Study: NCT01776138

Intervention type: OTHER
Intervention: Collect Blood and Survey Instruments
Study: NCT00025675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Study: NCT03413267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custard
Description: Food matrix: custard (liquid emulsion)
Study: NCT01968876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Adherence Smartphone App
Description: MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
Study: NCT00603044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate
Description: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
Study: NCT03413267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flan
Description: Food matrix: flan (soft gel)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sponge cake
Description: Food matrix: sponge cake (porous and spongy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biscuit
Description: Food matrix: biscuit (thick and crunchy)
Study: NCT00655941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary instruction
Description: Weekly instruction by dieticians

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised exercise in groups
Study: NCT04488211

Intervention type: OTHER
Intervention: Survey
Description: The IVM survey will be structured as a series of open questions and multiple-choice questions.
Study: NCT01419262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D - Cholecalciferol 400 IU
Description: One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 - Cholecalciferol 2000 IU
Description: One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
Study: NCT02277613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMI MultiStem cells
Description: AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
Study: NCT02179632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to disclosure website
Description: Participants are exposed to a physician payment disclosure website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to disclosure website
Description: Participants are exposed to a physician payment disclosure website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to disclosure website
Description: Participants are exposed to a physician payment disclosure website.
Study: NCT02682329

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Peroxide and Carbamide Peroxide
Description: Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Peroxide and Carbamide Peroxide
Description: Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Peroxide and Carbamide Peroxide
Description: Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
Study: NCT02458456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Isometric exercise using a hand dynamometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Isometric exercise using a hand dynamometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Isometric exercise using a hand dynamometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Isometric exercise using a hand dynamometer.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric resistance training
Description: Isometric exercise using a hand dynamometer.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric resistance training
Description: Isometric exercise using a hand dynamometer.
Study: NCT04068584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Angel
Description: Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Angel
Description: Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
Study: NCT03816501

Intervention type: OTHER
Group type: OTHER
Intervention: music
Description: The preference of the patients will be listened to preoperatively through the headphones

Intervention type: OTHER
Group type: OTHER
Intervention: no music
Description: the patients will not be listened
Study: NCT02789722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yerba Mate Extract
Description: Yerba Mate extract capsules 750 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 3 capsules, 3 times daily for 28 days.
Study: NCT02682329

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen Peroxide and Hydrogen Peroxide
Description: Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
Study: NCT02436239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone tablets, once daily, oral administration
Study: NCT03541577

Intervention type: DEVICE
Intervention: TruePhysioTM Microcatheter
Description: Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).

Intervention type: DEVICE
Intervention: Pressure Wire
Description: Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
Study: NCT01750021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat low carbohydrate diet
Description: 70E% fat, 20E% protein, 10E% carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat high carbohydrate diet
Description: 20E% fat, 20E% protein, 60E% carbohydrates
Study: NCT03693027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PTx800 lozenges
Description: PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
Study: NCT01158612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: infusion of Growth hormone in the patella tendon.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Growth Hormone
Description: infusion of Growth hormone in the patella tendon.
Study: NCT02051101

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy sample from Port Wine Stain Birthmark
Description: Biopsy sample from Port Wine Stain Birthmark
Study: NCT04801914

Intervention type: PROCEDURE
Intervention: Percutaneous biliary drainage
Description: Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).
Study: NCT04422587

Intervention type: OTHER
Intervention: RECOP unit patient
Description: All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
Study: NCT04238845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AQSP Administration
Description: Three days treatment of all children with AQSP for SMC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQSP Administration
Description: Three days treatment of all children with AQSP for SMC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQSP Administration
Description: Three days treatment of all children with AQSP for SMC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Plumpy'Doz
Description: Daily supplementation of children with Plumpy'Doz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with Vitamin A
Description: Single dose supplementation with Vitamin A to all children

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Vitamin A
Description: Single dose supplementation with Vitamin A to all children

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Vitamin A
Description: Single dose supplementation with Vitamin A to all children

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Zinc
Description: Daily supplementation with Zinc
Study: NCT00624338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Description: 75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: 150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.